Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors

This publication has 28 references indexed in Scilit:

• Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
  New England Journal of Medicine, 2000
• Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis
  JAMA, 2000
• The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
  Clinical Therapeutics, 1999
• Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator-controlled clinical trial
  Clinical Therapeutics, 1999
• A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
  Gastroenterology, 1999
• CYCLOOXYGENASES 1 AND 2
  Annual Review of Pharmacology and Toxicology, 1998
• Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs
  New England Journal of Medicine, 1998
• Primary gastroduodenal prophylaxis with omeprazole for non‐steroidal anti‐inflammatory drug users
  Alimentary Pharmacology & Therapeutics, 1998
• Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure
  Archives of internal medicine (1960), 1996
• Nonsteroidal Anti‐Inflammatory Drugs: Effects on Kidney Function
  The Journal of Clinical Pharmacology, 1991